Table 2. Baseline characteristics of patients with endophthalmitis in 20G vs MIVS group.
Baseline characteristics | 20 G (n = 40) | MIVS (n = 5) | Overall (n = 45) | p-value | |
---|---|---|---|---|---|
Age | Less than 50 years | 18 (45.0%) | 4 (80.0%) | 22 (48.9%) | 0.172 |
More than 50 years | 22 (55.0%) | 1 (20.0%) | 23 (51.1%) | ||
Sex | Male | 26 (65.0%) | 5 (100%) | 31 (68.9%) | 0.235 |
Female | 14 (35.0%) | 0 (0.0%) | 14 (31.1%) | ||
Immune predisposition | None | 16 (40.0%) | 3 (60.0%) | 19 (42.2%) | |
Diabetes | 19 (47.5%) | 2 (40.0%) | 21 (46.7%) | 0.808 | |
Steroids (oral) | 5 (12.5%) | 0 (0.0%) | 5 (11.1%) | ||
Any infective foci | Tooth caries | 1 (2.5%) | 0 (0.0%) | 1 (2.2%) | |
Intra-ocular surgery within 1 year prior to vitrectomy | Yes | 4 (10.0%) | 3 (60.0%) | 7 (15.5%) | 0.004 |
Indication for PPV | Vitrectomy for Vascular retinopathies | 18 (45.0%) | 2 (40.0%) | 20 (44.4%) | 0.832 |
Vitrectomy for uveitis | 6 (15.0%) | 0 (0.0%) | 6(13.3%) | ||
Vitrectomy for macular pathologies | 4 (10.0%) | 1 (20.0%) | 5 (11.1%) | 0.502 | |
Traumatic vitreous hemorrhage | 1 (2.5%) | 1 (20.0%) | 2 (4.4%) | 0.074 | |
ROP | 1 (2.5%) | 0 (0.0%) | 1 (2.2%) | ||
RRD | 8 (20.0%) | 0 (0.0%) | 8 (17.8%) | ||
Nucleus drop/ sub-luxated lens | 2 (5.0%) | 1 (20.0%) | 3 (6.7%) | 0.205 | |
Procedure performed | Vitrectomy alone | 25 (62.5%) | 4 (80.0%) | 29 (64.4%) | 0.641 |
Vitrectomy + anterior segment procedure combined | 15 (37.5%) | 1 (20.0%) | 16 (35.5%) | ||
Duration of Surgery (hrs) | ≤2 hrs >2 hrs |
21 (52.5%) 19 (47.5%) |
4 (80.0%) 1 (20.0%) |
25 (55.5%) 20 (44.4%) |
0.362 |
No. of Sclerotomies | 3 | 39 (97.5%) | 5 (100%) | 44 (97.8%) | 1.000 |
4 | 1 (2.5%) | 0 (0.0%) | 1 (2.2%) | ||
Tamponade | No tamponade | 22 (55.0%) | 5 (100%) | 27 (60.0%) | 0.073 |
Tamponade | 18 (45.0%) | 0 (0.0%) | 18 (40.0%) | ||
Lens status at closure | Phakic | 17 (42.5%) | 1 (20.0%) | 18 (40.0%) | 0.634 |
Not Phakic | 23 (57.5%) | 4 (80.0%) | 27 (60.0%) |
PPV: Pars plan vitrectomy, Sx: surgery, ROP: retinopathy of prematurity, RRD: Rhegmatogenous retinal detachment, SOI: silicone oil, C3F8: Perfluropropane